INNIO
22.9.2021 14:03:07 CEST | Business Wire | Press release
As part of its ongoing commitment to environmental stewardship, INNIO today announced the publication of its inaugural Sustainability Report, “Together for a Sustainable Future .” The theme of this report encompasses engagement of everyone -- with “together” being the key word indicating responsibility of all stakeholders in a journey to shape a sustainable future. The report highlights INNIO’s commitment to instituting a culture of transparency, providing progress updates and direction on INNIO’s global approach to sustainability covering its environmental, social, and governance (ESG) performance for 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210922005273/en/
In continuing its sustainability journey, INNIO’s leadership and its Sustainability Review Board (SRB) laid out the company’s ESG goals and strategy which included the development and publication of its first Sustainability Report. The report details how INNIO is working responsibly to deliver communities, industry, and the public with access to sustainable, reliable, and economical power while creating and maintaining an innovative, diverse, inclusive, pleasant and safe working environment for its employees.
Further, as INNIO’s Jenbacher and Waukesha products, services and digital solutions help unlock the transition to a carbon neutral future, INNIO’s Sustainability Report provides its stakeholders with indicators on commitment and progress to reducing greenhouse emissions and initiatives around responsible resource management.
In his opening note to the Sustainability Report, INNIO president and CEO, Carlos Lange, laid out key priorities and accomplishments:
Sustainability Goals
“As we continue to implement our enterprise strategy for profitable growth, we are also underlining our commitment to climate challenges and sustainable growth. INNIO’s Sustainability Goals are related to safety, energy and emissions, water, waste, building efficiency, circular economy, jobsite efficiency and sustainability of our products, services and solutions.”
Uninterrupted Access to Products and Services
“Along with our distributors and suppliers, INNIO is working to help ensure uninterrupted access to the products and services that our global customers rely on to support society during these difficult times. The recent COVID-19 global pandemic presented new challenges around the world, and INNIO was designated by many governments as an ‘essential’ enterprise since our products, parts and services support key infrastructure in the supply of natural gas and electrical energy. Customers use our products to provide primary and standby power & heat to homes; essential facilities such as hospitals, utilities, or district heating plants; and other businesses that must continue to operate.”
Technology Leadership: Hydrogen
“In Hamburg, INNIO Jenbacher and HanseWerk Natur recently collaborated to commission the world’s first large-scale gas engine in the 1 MW range capable of running on a variety of hydrogen-natural gas mixtures or on 100% green hydrogen. It’s also the world’s first natural gas engine conversion to hydrogen in the field. Again, INNIO technology is ahead of the game, demonstrating the future-proof nature of the installed base, this time by offering the ability to convert to carbon free, 100% hydrogen capabilities.”
Digitalization
“Through digitalization, we can constantly improve our products’ design and construction in our advanced factories, flawlessly execute our services, and move beyond reactive to predictive data solutions. At our manufacturing plants, we have embraced digitalization and are continuously refining our operations, accelerating innovation and improving our customers’ experience.”
The Sustainability Report publication follows recent sustainability activities that include INNIO’s recognition by EcoVadis with a Silver business sustainability rating , and INNIO’s joining the United Nations Global Compact . Each of these efforts underscores INNIO’s holistic and structured approach to incorporating sustainability across the company, considering the environment, employee development, health and safety, diversity and inclusion, as well as corporate responsibility.
INNIO’s Sustainability Report was developed in collaboration with external ESG advisors and subject matter experts as well as internal directors from diverse backgrounds.
About INNIO
INNIO is a leading provider of renewable gas, natural gas, and hydrogen-rich solutions and services for power generation and gas compression at or near the point of use. With our Jenbacher and Waukesha gas engines, INNIO helps to provide communities, industry and the public access to sustainable, reliable and economical power ranging from 200 kW to 10 MW. We also provide life-cycle support and digital solutions to the more than 53,000 delivered gas engines globally, through our service network in more than 100 countries. We deliver innovative technology driven by decarbonization, decentralization, and digitalization to help lead the way to a greener future. Headquartered in Jenbach, Austria, the business also has primary operations in Welland, Ontario, Canada, and Waukesha, Wisconsin, U.S. For more information, visit the company's website at www.innio.com . Follow INNIO on Twitter and LinkedIn .
At INNIO, we recognize that the growth of global economies and the industrialization that has accompanied this growth are directly impacting the future of our planet. We agree with the goals of the Paris Agreement—to stop global warming and lower temperatures to pre-industrial era levels by 2050. That’s why we took important steps in 2020 to address INNIO’s sustainability strategy, diving into the material issues we identified as the touchpoints to our customers and stakeholders. Our society faces unprecedented economic, environmental, social, and cultural challenges, and we are convinced that sustainability is the key to transforming these challenges into opportunities. Our sustainability strategy recognizes INNIO’s social and environmental responsibility. We must act now on this responsibility.
INNIO’s Sustainability Report is a non-financial disclosure presented for calendar year 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005273/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
